

# The Association of Gene Polymorphisms of the Angiotensin-Converting Enzyme and Angiotensin II Receptor Type 1 with Ischemic Stroke in Turkish Subjects of Trakya Region

*Anjiyotensin Dönüştürücü Enzim ve Anjiyotensin II Tip 1 Reseptörü Gen Polimorfizmlerinin Trakya Bölgesindeki Türk Hastalarda Görülen İskemik İnme ile İlişkisi*

Tammam SİPAHİ<sup>1</sup>, Babürhan GÜLDİKEN<sup>2</sup>, Sibel GÜLDİKEN<sup>3</sup>, Sedat ÜSTÜNDAĞ<sup>3</sup>, Nilda TURGUT<sup>2</sup>,  
Metin BUDAK<sup>1</sup>, Suat ÇAKİNA<sup>1</sup>, Hülya ÖZKAN<sup>4</sup>, Seralp ŞENER<sup>1</sup>

*Departments of <sup>1</sup>Biophysics, <sup>2</sup>Neurology, <sup>3</sup>Internal Medicine, Medical Faculty of Trakya University, Edirne;*

*<sup>4</sup>Department of Neurology, Social Security Hospital, Edirne*

**Submitted / Başvuru tarihi:** 31.07.2008 **Accepted / Kabul tarihi:** 02.09.2008

**Objectives:** The aim of this study was to investigate the frequency of ACE insertion/deletion (I/D) and AT1R (A1166C) gene polymorphisms in ischemic stroke patients in Trakya region and the relation between these gene polymorphisms and stroke subtypes and vascular risk factors.

**Patients and Methods:** The study involved 162 patients with ischemic stroke and 146 control subjects. Ischemic stroke patients were divided into large and small vessel disease subgroups according to ORG 10172 in Acute Stroke Treatment TOAST criteria. The ACE I/D polymorphism was investigated using polymerase chain reaction (PCR), and the AT1R (A1166C) polymorphism was identified using PCR and restriction fragment length polymorphism (RFLP) assay.

**Results:** The ACE I/D genotype distribution in patients (DD=34.0%, ID=50.0%, II=16.0%) did not differ from those in controls (DD=34.3%, ID=49.7%, II=16.1%). The AT1R A1166C genotype distribution in patients (AA=58.0%, CA=34.6%, CC=7.4%) did not significantly differ from those in controls (AA=60.1%, CA=35.7%, CC=4.2%). There was also no difference among the stroke subgroups regarding the distribution of ACE I/D and AT1R (A1166C) polymorphisms.

**Conclusion:** Our results show that ACE I/D and AT1R (A1166C) gene polymorphisms were not genetic risk factors for ischemic stroke in subjects in Trakya region.

**Key words:** ACE I/D gene polymorphism; AT1R (A1166C) gene polymorphism; ischemic stroke; renin-angiotensin system.

**Amaç:** Bu çalışmanın amacı, Trakya bölgesinde yaşayan iskemik inme geçirmiş hastalarda ACE insersiyon/delesyon (I/D) ve AT1R (A1166C) gen polimorfizmlerinin sıklığını, vasküler risk faktörleri ve inme alt-grupları ile ilişkisini araştırmaktır.

**Hastalar ve Yöntemler:** Çalışmaya 162 iskemik inme geçirmiş hasta ile 146 sağlıklı olgu alındı. İskemik inme hastaları, ORG 10172 Akut İnme Tedavisi (TOAST) kriterlerine göre büyük ve küçük damar hastalığı olarak inme alt gruplarına ayrıldı. ACE I/D polimorfizmi polimeraz zincir reaksiyonu (PZR), AT1R (A1166C) gen polimorfizmi ise PZR ve restriksiyon fragment uzunluk polimorfizmi (RFLP) yöntemleri kullanılarak yapıldı.

**Bulgular:** Hasta grubundaki ACE I/D genotip dağılımı (DD=34.0%, ID=50.0%, II=16.0%), kontrol grubu ile karşılaştırıldığında (DD=34.3%, ID=49.7%, II=16.1%) fark bulunmadı. Ayrıca hasta grubundaki AT1R (A1166C) genotip dağılımları ile (AA=58.0%, CA=34.6% ve CC=7.4%) kontrol grubu ile karşılaştırıldığında (AA=60.1%, CA=35.7% ve CC=4.2%) anlamlı fark saptanmadı. Her iki inme alt grubu arasında ACE I/D ve AT1R (A1166C) polimorfizmlerinin dağılımı açısından farklılık bulunmadı.

**Sonuç:** Çalışmamızda Trakya bölgesinde yaşayan insanlarda ACE I/D ve AT1R (A1166C) gen polimorfizmlerinin iskemik inme gelişmesinde genetik risk faktörleri olmadıkları belirlendi.

**Anahtar sözcükler:** İskemik inme; ACE I/D gen polimorfizmi; AT1R (A1166C) gen polimorfizmi; renin-anjiyotensin sistemi.

During the last two decades, there has been an increasing interest in the study of the different polymorphisms of genes of the renin-angiotensin system (RAS) and its association with the pathogenesis of essential hypertension,<sup>[1]</sup> ischemic heart disease,<sup>[2]</sup> coronary artery disease,<sup>[3]</sup> myocardial infarction,<sup>[4]</sup> stroke,<sup>[5-7]</sup> and progressive renal disease.<sup>[8]</sup> The RAS plays a central role in the regulation of blood pressure, sodium metabolism and renal hemodynamics.<sup>[9,10]</sup> The RAS gene system comprises the angiotensinogen (AGT), renin, angiotensin I, angiotensin I-converting enzyme (ACE), angiotensin II, and angiotensin II receptor types 1, 2, 3 and 4 (AT1R, AT2R, AT3R and AT4R) genes.<sup>[11]</sup>

The ACE is a key component of both the RAS and the kinin-kallikrein system (Fig. 1). ACE cleaves the carboxy-terminal dipeptide of angiotensin I, releasing the physiologically active octapeptide angiotensin II.<sup>[12]</sup> Angiotensin II is a potent vasoconstrictive molecule that plays a key role in modulating vascular tone. Angiotensin II exerts its effects by binding to AT1R, AT2R, AT3R and AT4R. The AT1R is the major mediator of physiological effects of angiotensin II. Human AT1R is present predominantly in vascular cells and in both kidney and adrenal gland mediating physiological actions of angiotensin II as shown in Figure 1. The AT1R mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system, followed by vasoconstriction, hypertrophy, or catecholamine liberation at sympathetic nerve endings.<sup>[13-19]</sup>

The ACE gene maps to chromosome 17 (17q23.3), spans 21 kb, and comprises 26 exons and 25 introns, and is characterized by a polymorphism resulting from the presence (insertion) or absence (deletion) of a 287 base pairs fragment of a repeated Alu sequence at intron 16 hence, the corresponding designation of insertion (I) or deletion (D) of the two resulting alleles.<sup>[20, 21]</sup>

The AT1R gene maps to chromosome 3 (3q21-q25), spans 45.123 kb, and comprises 5 exons and 4 introns.<sup>[22]</sup> AT1R entire coding region

harbored only on exon 5, and is characterized by a polymorphism resulting from an A/C (adenine/cytosine) transversion located at position 1166 (A1166C polymorphism) in 3' untranslated region.<sup>[23]</sup>

Since AT1R (A1166C) and ACE I/D polymorphisms have been reported,<sup>[23,24]</sup> they have been widely examined in association with various diseases.<sup>[2-6]</sup>

In view of the aging population stroke is becoming a major problem, it is the most frequent disease leading to disability,<sup>[25]</sup> and estimates forecast a continuing increase in the incidence, prevalence, and mortality of stroke in the next decades. Evidence is accumulating that genetic factors contribute to the risk of stroke.<sup>[26,27]</sup> Some investigators have suggested that genetic factors, which appear insignificant when occurring alone, may increase susceptibility to stroke in the presence of other risk factors as hypertension, diabetes mellitus, smoking, and alcohol consumption.<sup>[28,29]</sup> Among potential candidate genes that predispose to stroke, ACE I/D, and AT1R (A1166C) polymorphisms have been implicated in the pathophysiology of stroke.<sup>[5,30]</sup> Coexisting risk factors, such as hypertension and high cholesterol levels, seem to increase the effects of these polymorphisms, although the available evidence remains inconclusive. Risk factors, underlying mechanisms and pathophysiologic responses to stroke vary according to the subtypes of stroke.<sup>[31]</sup> And this prompted us to initiate to assess the influence of the ACE I/D, and AT1R (A1166C) polymorphisms, and their interaction with coexisting risk factors, on the risk of ischemic stroke subtypes.

## PATIENTS AND METHODS

The study included 308 Turkish individuals from Trakya region, who were informed of the study protocol, comprising 162 patients with ischemic stroke (85 males, 77 females; mean age 67±11 years) which were categorized according to the trial of ORG 10172 in Acute Stroke Treatment (TOAST) into large and small vessel stroke subtypes, and 146 healthy individuals as a control group (37 males, 109 females; mean age




Fig. 1. Renin-angiotensin and Kinin-Kallikrein systems.

62±11 years) for the distribution of the polymorphisms. Approval for the study was obtained from the Ethics Committee of Trakya University School of Medicine.

For DNA isolation; e.Z.N.A. blood DNA kits were purchased from Omega Bio-tek (BOGA), Istanbul, Turkey. All reagents for PCR, RFLP and gel electrophoresis were purchased from Fermentas Life Sciences (ELIPS), Istanbul, Turkey.

#### DNA isolation

Peripheral blood (2 ml) was collected into tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. DNA was isolated from peripheral blood, containing EDTA, by e.Z.N.A. (EaZy Nucleic Acid Isolation) blood DNA kits (Omega Bio-tek Doraville USA).

DNA purity and quantity were assessed by absorbance values in spectrophotometer and checked by 0.8% agarose gel electrophoresis.

#### Analysis of polymorphisms of ACE and AT1R genes

##### Genotyping of ACE gene polymorphism


To determine the ACE gene I/D polymorphism of the patients and control groups, a genomic DNA fragments on intron 16 of the ACE gene was amplified by PCR in a 15 µl PCR reaction mixture containing 100 ng of DNA, dNTP (0.2 mM of each), upstream and downstream oligonucleotide primers (300 pmol), 1X Taq Buffer with (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (75 mM Tris-HCl pH 8.8, 20 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.01% Tween 20), 2.5 mM MgCl<sub>2</sub> and 0.75 U of Taq DNA polymerase (Fermentas Life Sciences). Amplification were performed with a Techne (TechGene) DNA Thermal Cycler with 5 min of denaturation at 94°C, followed by 30 cycles with denaturation for 1 min at 94°C, annealing for 1 min at 58°C, and extension for 1 min at 72°C, followed by 7 min of extension at 72°C.<sup>[32]</sup>

The PCR primers with the sequences reported by Rigat B et al.<sup>[32]</sup> were used (sense and anti-sense primers were; 5'-CTGGAGACCACTCCCATCCTTTCT-3' and 5'-GATGTGGCCATCACATTCGTCAGAT-3', respectively). The expected I and D alleles, 490 and 190 base pairs in size, were visualized after electrophoresis on a 2% agarose gel and ethidium bromide staining (Fig. 2). Preferential amplification of the D allele in the heterozygotes has led to their mistyping as DD homozygotes.<sup>[33,34]</sup> To exclude this possibility, all DD homozygotes were retyped using I allele specific sense primer 5'-TTTGAGACGGAGTCTCGCTC-3' and anti-sense primer reported by Rigat B et al.<sup>[32]</sup> was used. Amplification was performed with a DNA Thermal Cycler with 3 min of denaturation at 93°C, followed by 30 cycles with 1 min of denaturation at 93°C, annealing for 1.5 min at 68°C, and extension for 2 min at 72°C, followed by 3 min of extension at 72°C. When a DD sample amplified using the I-specific primer, it was retyped ID.


### Genotyping of the AT1R A1166C gene polymorphism

A1166C polymorphism of AGTR<sub>1</sub> was identified with PCR followed by RFLP with the restriction enzyme *Hae*III. PCR primers were generated to amplify the 255 bp fragment encompassing the A1166C variant (sense and anti-sense primers were 5'-GCAGCACTTCACTACCAAATGGGC-3' and 5'-CAGGACAAAAGCAGGCTAGGGAGA-3', respectively) in a 25 µl PCR mixture con-

taining 200 ng of DNA, dNTP (0.2 mM of each), sense and antisense primers (500 pmol of each), 1X Taq buffer with (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (75 mM Tris-HCl (Ph 8.8), 20 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.01% Tween 20), 1.5 mM MgCl<sub>2</sub> and 1.25 U of Taq DNA polymerase. Amplification were performed with a Techne (TechGene) DNA Thermal Cycler with 5 min of denaturation at 94°C, followed by 35 cycles with denaturation for 1 min at 94°C, annealing for 1 min at 55°C, and extension for 1 min at 72°C, followed by 7 min of extension at 72°C. Ten microliters of PCR product were digested with 5 unite of the restriction enzyme *Hae*III (Takara Bio Inc, Japan) in 1 X M buffer (10mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM Dithiothreitol and 50mM NaCl) for 2 hours at 37°C. When mutant allele (cytosine), digested with *Hae*III that yield tow fragments 231 bp and 24 bp, whereas a wild allele (adenine) at nucleotide position 1166, had no cutting site for *Hae*III, so that the 255 bp PCR product was not cleaved into 231 bp and 24 bp fragments.<sup>[35,36]</sup> The restriction digest products were visualized after electrophoresis on a 2% agarose gel and ethidium bromide staining (Fig. 3).



**Fig. 2.** Ethidium bromide-stained 2% agarose gel of representative PCR products of ACE gene I/D polymorphism shows the D allele (190 bp, lane 7, 9, and 11), the ID genotype (190 bp, and 490 bp, lane 2, 4, 5, 6, 8, and 10) and the I allele (490 bp, lane 1, and 3); lane 50 bp is a size marker (GeneRuler 50bp DNA Ladder-Fermentas Life Sciences).



**Fig. 3.** Ethidium bromide-stained gel of representative PCR products of AGTR<sub>1</sub> gene A1166C polymorphism shows the AA genotype (255 bp, lane 2, 3, 7, and 8), the AC genotype (255 bp, 231 bp, and 24 bp (not detectable in agarose gel) lane 5, 6, 9, and 11), and the CC genotype (231 bp, lane 1, 4, and 10); lane O'GR is a size marker (O'GeneRuler 100bp DNA Ladder-Fermentas Life Sciences).

In all PCR experiments, for ACE and AGTR<sub>1</sub> genes, several reactions containing no DNA were included to control the possibility of contamination.

**Statistical analysis**

Statistical analyses were performed with the SPSS 15.0 software and STATA program, version 8. Normality of distribution was checked by using the Kolmogorov-Smirnov test. If the test distribution was found normal, Independent-Samples T test was used to evaluate differences in continuous variables between controls and patients with large vessel disease and patients with small vessel disease. In this condition, the data are presented as mean ± standard deviation (SD). As variables did not have normal distribution, Mann-Whitney U test was used to evaluate differences in continuous variables between controls and patients with large vessel disease and patients with small vessel disease. In this condition, the data are presented as median (25-75 percentiles). Chi-square test was performed to determine the differences in dichotomized variables between control and patient group. Allele frequencies were calculated from the genotypes of all subjects. Hardy-Weinberg equilibrium was assessed by chi-square analysis. Allele and genotype frequencies were compared by standard contingency table analysis using chi-square test. Significance was defined as p<0.05.

**RESULTS**

The control group was younger than the patient group, and had lower systolic blood pressures, diastolic blood pressures, fasting blood glucose

**Table 1. Demographic and clinical characteristics of the control and stroke groups**

	Control group (n=146)	p	Stroke group (n=162)
Gender (M/F)	37/109	<0.001	85/77
Hypertension (%)	62.1	<0.001	85.6
Current smoker (%)	3.7	<0.001	28.2
Diabetes mellitus	17.9	0.008	31.3
Family history of stroke (%)	17.9	0.007	34.1
Age (years)	62 (53-72)	0.001	70 (60-74)
SBP (mmHg)	120 (110-130)	<0.001	140 (120-160)
DBP (mmHg)	70 (70-80)	<0.001	80 (70-90)
FBG (mg/dl)	89.5 (82-105.5)	<0.001	102 (90-128)
TG (mg/dl)	116.0 (81.8-174.5)	NS	136.5 (90.8-136.5)
TC (mg/dl)	189 (169-214.8)	NS	190.5 (166-219)
HDL-C (mg/dl)	39 (32-50.5)	NS	38 (31-46)
LDL-C (mg/dl)	120±33	NS	125±38

Values are given as mean ± SD. SBP and DBP: Systolic and diastolic blood pressures; FBG: Fasting blood glucose; TG: Triglycerides; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; NS: Non-significant.

levels than the patients (p<0.001). The controls were predominantly female (74.7%), whereas the patients were very similar between the male and the female subjects (p<0.001). The patient group had a higher prevalence of hypertension, smoking, diabetes mellitus and family history of stroke compared with the controls (p<0.001, p<0.001, p<0.01, and p<0.01, respectively). Demographic and clinical characteristics of the control and stroke patient subjects are given in Table 1.

No interaction was found between the studied polymorphisms and biochemical parameters and vascular risk factors.

**Table 2. Distributions of ACE genotype and allele frequencies in the controls and stroke patient subjects**

	ACE genotype frequency*			ACE allele frequency*	
	DD	ID	II	D	I
Control group (%)	34.3	16.1	49.7	59	41
Stroke group (%)	34.0	16.0	50.0	59	41

\*Non-significant between groups.

**Table 3. Distributions of AGTR<sub>1</sub> genotype and allele frequencies in the controls and stroke patient subjects**

	AGTR <sub>1</sub> genotype frequency*			AGTR <sub>1</sub> allele frequency*	
	AA	AC	CC	A	C
Control group (%)	60.1	4.2	35.7	78	22
Stroke group (%)	58.0	7.4	34.6	75.3	24.7

\*Non-significant between groups.

**Table 4. Demographic and clinical characteristics of the stroke subtypes classified according to TOAST criteria**

	Large vessel disease	<i>p</i>	Small vessel disease
Gender (% F)	50	NS	39
Hypertension (%)	85	NS	85.1
Current smoker (%)	27.5	NS	27.7
Diabetes mellitus	45	NS	28.4
Family history of stroke (%)	36.8	NS	38.4
Age (years)	66±11	NS	67±10
SBP (mmHg)	138±21	NS	145±27
DBP (mmHg)	80 (80-90)	NS	80 (80-92.5)
FBG (mg/dl)	109.5 (94.8-137.8)	0.021	102 (92-121)
TG (mg/dl)	114 (86.3-162.8)	NS	167.5 (93.5-239)
TC (mg/dl)	199±42	NS	192±51
HDL-C (mg/dl)	40±12	NS	37±12
LDL-C (mg/dl)	129±39	NS	123±42

Values are given as mean ± SD. SBP and DBP: Systolic and diastolic blood pressures; FBG: Fasting blood glucose; TG: Triglycerides; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; NS: Non-significant.

Table 2 shows the distributions of ACE genotype and allele frequencies in the controls and stroke patient subjects. The distributions of AGTR<sub>1</sub> genotype and allele frequencies in the controls and stroke patient subjects are shown in Table 3.

Table 4 shows the demographic and clinical characteristics of the stroke subtypes classified according to TOAST criteria. The difference within the ischemic stroke subgroups was also

not significant for ACE I/D and AT1R A1166C genotype distribution and allelic frequency Table 5, 6.

## DISCUSSION

Several studies have shown a high prevalence of the D allele of ACE gene and C1166 allele of AT1R among patients with stroke disease.<sup>[6,37-39]</sup> On the other hand, researches have shown no differences in the allele frequencies and genotype distributions of ACE and AT1R gene polymorphisms between the healthy and stroke disease groups.<sup>[40,41]</sup> Studies analyzing the gene-gene and gene-environment interactions in stroke have revealed much of useful information. The increasing knowledge has proved to be very consistent. The apparent contradictions can be solved after careful examination. The diverse data only reflect the diverse aspects of the complex interactions. The differences in the results can also stem from distinctions in ethnicity.

In our study, the overall frequencies of the genotypes DD, ID, and II in patient group were 34.0%, 50.0% and 16.0% did not differ from genotype distribution in healthy group 34.3%, 49.7% and 16.1%. No differences were detected in alleles (D or I) frequency between the healthy and ischemic stroke groups. Additionally, our results showed no significant difference in either the genotypic distribution or allelic frequency among the stroke subtypes. Our study supports the study which was done in Istanbul region by Tuncer et al.<sup>[7]</sup> They reported that the ACE I/D polymorphisms were not associated with ischemic stroke and its subtypes. On the other hand,

**Table 5. Distributions of ACE genotype and allele frequencies in the stroke patients classified according to TOAST criteria**

	ACE genotype frequency*			ACE allele frequency*	
	DD	ID	II	D	I
Large vessel disease (%)	37.5	15.0	47.5	38.7	61.3
Small vessel disease (%)	37.3	16.4	46.3	39.5	60.5

\*Non-significant between groups.

**Table 6. Distributions of AGTR<sub>1</sub> genotype and allele frequencies in the stroke patients classified according to TOAST criteria**

	AGTR <sub>1</sub> genotype frequency*			AGTR <sub>1</sub> allele frequency*	
	AA	AC	CC	A	C
Large vessel disease (%)	57.5	10.0	32.5	73.8	26.2
Small vessel disease (%)	52.2	7.5	40.3	72.4	27.6

\*Non-significant between groups.

the overall frequencies of the genotypes AA, CA, and CC in patient group 58.0%, 34.6% and 7.4% did not differ from genotype distribution in healthy group 60.1%, 35.7% and 4.2%, respectively. No statistical differences were detected in alleles (A or C) frequency between the healthy and ischemic stroke groups. No interactions between the studied polymorphisms and biochemical parameters were found.

The observed genotype frequencies are in agreement with frequencies predicted by Hardy-Weinberg equilibrium. Statistical analysis have shown no statistically significant difference between the frequencies of the genotype of the two groups, and have not verified a relationship between ACE I/D and AT1R A1166C genotype polymorphisms and the development of ischemic stroke in Turkish subjects of Trakya region.

Two-thirds of strokes occur in people over the age of 65. In our study, the mean age of the patients with ischemic stroke was 67±11 years. But, patients with young-onset stroke are thought to possess a stronger genetic background than those who have stroke relatively late in life. The present study has limitation regarding the small sample of young-onset stroke. So, further studies including large samples of young-onset stroke are needed to clarify the role of ACE I/D and AT1R A1166C gene polymorphisms in ischemic stroke in Turkish patients of Trakya region.

## REFERENCES

1. Thiel B, Weder AB. Genes for Essential Hypertension: Hype, Help, or Hope? *J Clin Hypertens* 2000;2:187-93.
2. Rice GL, Foy CA, Grant PJ. Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease. *Cardiovasc Res* 1999;41:746-53.
3. Taniguchi I, Yamazaki T, Wagatsuma K, Kurusu T, Shimazu Y, Takikawa K, et al. The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery disease and coronary stent restenosis in Japanese patients. *Jpn Circ J* 2001;65:897-900.
4. Araújo MA, Goulart LR, Cordeiro ER, Gatti RR, Menezes BS, Lourenço C, et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. *Int J Cardiol* 2005;103:27-32.
5. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. *J Neurol Neurosurg Psychiatry* 1998;64:227-30.
6. Hong SH, Park HM, Ahn JY, Kim OJ, Hwang TS, Oh D, et al. ACE I/D polymorphism in Korean patients with ischemic stroke and silent brain infarction *Acta Neurol Scand* 2008;117:244-9.
7. Tuncer N, Tuglular S, Kiliç G, Sazci A, Us O, Kara I. Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke. *J Clin Neurosci* 2006;13:224-7.
8. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. *Nephrol Dial Transplant* 2006;21:979-83.
9. Matsubara M. Genetic determination of human essential hypertension. *Tohoku J Exp Med* 2000;192:19-33.
10. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. *Nature* 1981;291:329-31.
11. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev* 2000;52:415-72.
12. Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. *J Hypertens* 1993;11:471-6.
13. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. *Biochemistry* 1989;28:5311-8.
14. Burns KD. Angiotensin II and its receptors in the diabetic kidney. *Am J Kidney Dis* 2000;36:449-67.
15. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. *Pharmacol Rev* 2000;52:11-34.
16. Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, Haji M, et al. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. *Biochem Biophys Res Commun* 1992;183:910-6.
17. Furuta H, Guo DF, Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. *Biochem Biophys Res Commun* 1992;183:8-13.
18. Griendling KK, Lassègue B, Alexander RW. The vascular angiotensin (AT1) receptor. *Thromb Haemost* 1993;70:188-92.
19. Fluharty SJ, Reagan LP, Yee DK. The angiotensin type 1 and type 2 receptor families. Siblings or cousins? *Adv Exp Med Biol* 1995;377:193-215.
20. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. *J Biol Chem* 1991;266:15377-83.
21. Mattei MG, Hubert C, Alhenc-Gelas F, Roedel N, Corvol P, Soubrier F. Angiotensin-I converting enzyme gene is on chromosome 17. *Cytogenet Cell Genet* 1989; 51:1041-5.
22. Szpirer C, Rivière M, Szpirer J, Levan G, Guo DF, Iwai N, et al. Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. *J Hypertens* 1993;11:919-25.

23. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* 1994;24:63-9.
24. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990;86:1343-6.
25. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. *Stroke* 1997;28:951-6.
26. Saver J, Tamburi T. Genetics of cerebrovascular disease. In: Pulst SM, editor. *Neurogenetics*. 1st ed. New York: Oxford University Press; 2000. p. 403-32.
27. Szolnoki Z. Evaluation of the interactions of common genetic mutations in stroke. *Methods Mol Med* 2005;104:241-50.
28. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CD. Ethnic differences in incidence of stroke: prospective study with stroke register. *BMJ* 1999;318:967-71.
29. Sacco RL. Newer risk factors for stroke. *Neurology* 2001;57(5 Suppl 2):S31-4.
30. Szolnoki Z, Melegh B. Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis. *Curr Med Chem* 2006;13:1627-34.
31. Güldiken B, Özkan H, Kabayel L. Akut iskemik inmede ortalama trombosit hacmi ve periferik kan hücre sayısı yanıtı. *Trakya Üniv Tıp Fak Derg* 2008;25:130-5.
32. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). *Nucleic Acids Res* 1992;20:1433.
33. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. *PCR Methods Appl* 1993;3:120-1.
34. van Ittersum FJ, de Man AM, Thijssen S, de Knijff P, Slagboom E, Smulders Y, et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. *Nephrol Dial Transplant* 2000;15:1000-7.
35. Berge KE, Berg K. Polymorphisms at the angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R) loci and normal blood pressure. *Clin Genet* 1998;53:214-9.
36. Mettimano M, Lanni A, Migneco A, Specchia ML, Romano-Spica V, Savi L. Angiotensin-related genes involved in essential hypertension: allelic distribution in an Italian population sample. *Ital Heart J* 2001;2:589-93.
37. Gao X, Yang H, ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. *Neurosci Lett* 2006;398:172-7.
38. Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, et al. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. *Neuromolecular Med* 2006;8:353-60.
39. Henskens LH, Kroon AA, van der Schouw YT, Schiffers PM, Grobbee DE, de Leeuw PW, et al. Renin-angiotensin system and nitric oxide synthase gene polymorphisms in relation to stroke. *Am J Hypertens* 2007;20:764-70.
40. Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. *J Hum Genet* 2007;52:205-19.
41. Pera J, Slowik A, Dziedzic T, Wloch D, Szczudlik A. ACE I/D polymorphism in different etiologies of ischemic stroke. *Acta Neurol Scand* 2006;114:320-2.